Abstract: New therapeutic uses of a triple agonistic long-acting conjugate or a triple and a farnesoid X receptor (FXR) agonist, or a combination further containing an acetyl-CoA carboxylase (ACC) inhibitor are disclosed. The triple agonistic long-acting conjugate or a triple and a farnesoid X receptor (FXR) agonist, or a combination further containing an acetyl-CoA carboxylase (ACC) inhibitor, may be for preventing or treating a liver disease.

Abstract: New therapeutic uses of a glucagon derivative or a conjugate thereof are disclosed. The glucagon derivative or a conjugate thereof is represented by the following formula: Y-X2-QGTF-X7-SDYSKY-X14-D-X16-X17-R-X19-X20-X21-FVQWLMNT-X30 (General Formula 1, SEQ ID NO: 46), and is effective in preventing or treating a liver disease. Therefore, the glucagon derivative or a conjugate thereof, or a pharmaceutical composition containing it as an active ingredient may be for preventing or treating a liver disease.

Abstract: Provided are a pharmaceutical composition including a long-acting conjugate of a triple agonist as an active ingredient and a method of treating obesity and/or a non-alcoholic fatty liver disease using the same. The pharmaceutical composition including the long-acting conjugate of the triple agonist of the present invention may be stably applied to treatment of obesity and/or a non-alcoholic fatty liver disease without side effects according to therapeutic effects on obesity and/or the non-alcoholic fatty liver disease.

Abstract: A liquid formulation of a long-acting conjugate of glucagon, GLP-1, and GIP trigonal agonist, and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 920 nmol/mL of a long-acting conjugate, a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 5.0 to 7.0, and 0.5% (w/v) to 10% (w/v) of a sugar alcohol, saccharide, or a combination thereof.

Abstract: A liquid formulation of a long-acting conjugate of GLP-2 and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 18,630 nmol/mL of a long-acting conjugate, a stabilizer, and a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 4.5 to 6.5.

Abstract: The present invention relates to an insulin analog conjugate and use thereof.

Abstract: The present invention relates to changes in interleukin-2 alpha receptors and interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors.

Abstract: Provided are a composite formulation including sitagliptin and dapagliflozin and a method of preparing the same.

Abstract: Provided are a pharmaceutical composite formulation and a method of preparing the same, the pharmaceutical composite formulation including: a first layer containing, as an active ingredient, a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant, and a second layer containing, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, and a mixture thereof.

Abstract: Provided is a novel method for preparing a long-acting drug conjugate and a long-acting drug conjugate prepared using the method.

Abstract: Provided is a novel method for preparing a long-acting drug conjugate and a long-acting drug conjugate prepared using the method.

Abstract: A method for improving the solubility of a physiologically active protein or peptide compared to that of a physiologically active protein or peptide which is not conjugated to an immunoglobulin Fc fragment is disclosed. The method includes steps of conjugating the physiologically active protein or peptide to an immunoglobulin Fc fragment. Also disclosed is a composition for improving the solubility of a physiologically active protein or peptide, which contains an immunoglobulin Fc fragment. The composition improves the solubility compared to a composition without an immunoglobulin Fc fragment.

Abstract: A liquid formulation of a long-acting conjugate of a peptide having activities for a glucagon receptor and a GLP-1 receptor, and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 940 nmol/mL of the long-acting conjugate, a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 4.5 to 7.5, and 1% (w/v) to 20% (w/v) of saccharide, and 0.001% (w/v) to 0.2% (w/v) of a nonionic surfactant.

Abstract: Polyethylene glycol derivatives of the following formula I and uses thereof are disclosed. A method for manufacturing the polyethylene glycol derivatives is also disclosed.

Abstract: This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

Abstract: A liquid formulation of a long-acting conjugate of glucagon, and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 936 nmol/mL of a long-acting conjugate, a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 4.8 to 6.5, and 1.

Abstract: A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

Abstract: Provided is a use of a triple glucagon/GLP-1/GIP receptor agonist or a long-acting conjugate thereof for treatment of hyperlipidemia.

Abstract: A use of GLP-2 and a long-acting conjugate thereof for preventing or treating mucositis induced by radiotherapy, chemotherapy, or a combination thereof is disclosed. The GLP-2, the long-acting conjugate thereof, or the composition including the same may be applied to preparation, treatment, and amelioration of mucositis induced by radiotherapy and/or chemotherapy.

Abstract: According to an aspect, provided are a composite tablet and a method of preparing the composite tablet, wherein the composite tablet may include a first layer including dry granules that include sitagliptin or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and dapagliflozin or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a second layer including wet granules that include metformin or a pharmaceutically acceptable salt thereof and colloidal silicon dioxide.